Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

NCT01298323 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
205
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi